Emanuel K. Manesis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emanuel K. Manesis has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
- George V. Papatheodoridis
1(st) Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece
12 shared publications Athanasios J. Archimandritis
Second Department of Internal Medicine, Athens University Medical School, “Hippokration” General Hospital of Athens; Greece
5 shared publications- Emmanouil A. Tsochatzis
Sheila Sherlock Liver Unit and UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom
4 shared publications Stephanos Hadziyannis
4 shared publicationsJohn Koskinas
2nd Academic Department of Internal Medicine, Hippokration General Hospital, and
3 shared publicationsMaria Schina
Liver Unit Euroclinic
3 shared publications
Latest Publications
- 17 October 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 157, 110557
Comparison of Visual Transient Elastography, Vibration Controlled Transient Elastography, Shear Wave Elastography and Sound Touch Elastography in Chronic liver Disease assessment using liver biopsy as ‘Gold Standard’
- 17 October 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 157, 110557
Comparison of Visual Transient Elastography, Vibration Controlled Transient Elastography, Shear Wave Elastography and Sound Touch Elastography in Chronic liver Disease assessment using liver biopsy as ‘Gold Standard’
- 10 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1187-1193
Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis
Liver stiffness measurements (LSMs) by 2-dimensional-shear-wave elastography (LSM2D-SWE) are now widely used in hepatology. However, relevant information for primary biliary cholangitis (PBC) is sc...
- 10 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1187-1193
Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis
Liver stiffness measurements (LSMs) by 2-dimensional-shear-wave elastography (LSM2D-SWE) are now widely used in hepatology. However, relevant information for primary biliary cholangitis (PBC) is sc...
- Open Access
- 18 March 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (9) , 1214-1222
Collagen proportionate area is an independent predictor of long‐term outcome in patients with non‐alcoholic fatty liver disease
Background: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies by measuring the amount of collagen deposition as a proportion of the total biopsy area. CPA predicts clinical outcomes in patients with HCV and can sub‐classify cirrhosis.Aim: To test the ability of CPA to quantify fibrosis and predict clinical outcomes in patients with NAFLD.Methods: We assessed consecutive patients with biopsy‐proven NAFLD from three European centres. Clinical and laboratory data were collected at baseline and at the time of the last clinical follow‐up or death. CPA was performed at two different objective magnifications, whole biopsy macro and ×4 objective magnification, named standard (SM) and high (HM) magnification respectively. The correlation between CPA and liver stiffness was assessed in a sub‐group of patients.Results: Of 437 patients, 32 (7.3%) decompensated and/or died from liver‐related causes during a median follow‐up of 103 months. CPA correlated with liver stiffness and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was significantly higher than SM CPA in stages F0‐F3 but similar in cirrhosis, reflecting a higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at baseline (HR: 1.04, 95% CI: 1.01‐1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI: 1.01‐1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02‐47.84) were independent predictors of liver‐related clinical outcomes at standard and competing risk multivariate Cox‐regression analysis.Conclusions: CPA accurately measures fibrosis and is an independent predictor of clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate endpoint in clinical trials.
- 18 March 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (9) , 1214-1222
Open AccessCollagen proportionate area is an independent predictor of long‐term outcome in patients with non‐alcoholic fatty liver disease
Background: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies by measuring the amount of collagen deposition as a proportion of the total biopsy area. CPA predicts clinical outcomes in patients with HCV and can sub‐classify cirrhosis.Aim: To test the ability of CPA to quantify fibrosis and predict clinical outcomes in patients with NAFLD.Methods: We assessed consecutive patients with biopsy‐proven NAFLD from three European centres. Clinical and laboratory data were collected at baseline and at the time of the last clinical follow‐up or death. CPA was performed at two different objective magnifications, whole biopsy macro and ×4 objective magnification, named standard (SM) and high (HM) magnification respectively. The correlation between CPA and liver stiffness was assessed in a sub‐group of patients.Results: Of 437 patients, 32 (7.3%) decompensated and/or died from liver‐related causes during a median follow‐up of 103 months. CPA correlated with liver stiffness and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was significantly higher than SM CPA in stages F0‐F3 but similar in cirrhosis, reflecting a higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at baseline (HR: 1.04, 95% CI: 1.01‐1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI: 1.01‐1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02‐47.84) were independent predictors of liver‐related clinical outcomes at standard and competing risk multivariate Cox‐regression analysis.Conclusions: CPA accurately measures fibrosis and is an independent predictor of clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate endpoint in clinical trials.
- 1 January 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (1) , 25-26
Immigration, European Union and health issues: A commentary
- 1 January 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (1) , 25-26
Immigration, European Union and health issues: A commentary
- 1 November 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 59 (5) , 949-956
Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study
- 1 November 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 59 (5) , 949-956
Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study
- 1 July 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 55 (1) , 61-68
Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B
- 1 July 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 55 (1) , 61-68
Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B
- 6 October 2009
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 30 (9) , 947-954
Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study
Summary: Background Chronic hepatitis C (CHC) induces insulin resistance (IR) and subsequently diabetes.Aim To examine viral, metabolic and histological predictors of IR in 275 CHC patients to test the hypothesis that IR differs among HCV genotypes and that viral replication directly affects IR.Methods We studied 275 nondiabetic treatment‐naïve CHC patients. Histological lesions were evaluated according to Ishak. IR was assessed using homeostasis model assessment for insulin resistance (HOMA‐IR).Results HOMA > 3.0 was found in 37% of patients, independently associated with higher BMI and GGT. In genotype non‐3 patients, HOMA > 3.0 was associated with higher BMI and GGT values, while no significant association was noted in genotype 3 patients. In non‐obese patients with minimal fibrosis, HOMA > 3.0 was found in 20% of cases without significant differences among genotypes. No association between HOMA > 3.0 and HCV‐RNA levels was found. Severe fibrosis (stage 5–6) related to older age (OR:1.048), HOMA‐IR (OR:1.177), necroinflammation (OR: 2.990) and higher ALT (OR: 1.009) and GGT (OR:1.006).Conclusions IR develops at early stages of CHC without significant differences among genotypes. It is more frequent in obese patients with steatosis and contributes to fibrosis progression. However, IR does not seem to be associated with viraemia and therefore its exact pathogenetic mechanism in CHC remains elusive.
- 6 October 2009
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 30 (9) , 947-954
Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study
Summary: Background Chronic hepatitis C (CHC) induces insulin resistance (IR) and subsequently diabetes.Aim To examine viral, metabolic and histological predictors of IR in 275 CHC patients to test the hypothesis that IR differs among HCV genotypes and that viral replication directly affects IR.Methods We studied 275 nondiabetic treatment‐naïve CHC patients. Histological lesions were evaluated according to Ishak. IR was assessed using homeostasis model assessment for insulin resistance (HOMA‐IR).Results HOMA > 3.0 was found in 37% of patients, independently associated with higher BMI and GGT. In genotype non‐3 patients, HOMA > 3.0 was associated with higher BMI and GGT values, while no significant association was noted in genotype 3 patients. In non‐obese patients with minimal fibrosis, HOMA > 3.0 was found in 20% of cases without significant differences among genotypes. No association between HOMA > 3.0 and HCV‐RNA levels was found. Severe fibrosis (stage 5–6) related to older age (OR:1.048), HOMA‐IR (OR:1.177), necroinflammation (OR: 2.990) and higher ALT (OR: 1.009) and GGT (OR:1.006).Conclusions IR develops at early stages of CHC without significant differences among genotypes. It is more frequent in obese patients with steatosis and contributes to fibrosis progression. However, IR does not seem to be associated with viraemia and therefore its exact pathogenetic mechanism in CHC remains elusive.
- 30 September 2009
- Published by Wiley in Hepatology Research
- Vol. 39 (10) , 972-978
Circulating and liver tissue levels of retinol‐binding protein‐4 in non‐alcoholic fatty liver disease
Aim: Retinol‐binding protein‐4 (RBP4) has been proposed as a new adipokine that regulates insulin action in muscles and the liver, and contributes to the pathogenesis of insulin resistance. As non‐alcoholic fatty liver disease (NAFLD) is related to insulin resistance, we aimed to evaluate RBP4 levels in the serum and liver of patients with NAFLD.Methods: Serum RBP4 was measured in 30 NAFLD patients and 30 matched healthy controls. RBP4 expression in the liver of NAFLD patients was shown by immunohistochemistry.Results: Serum RPB4 was significantly lower in NAFLD patients compared with controls (25.15 vs 34.66 µg/mL, P < 0.001) and there was no correlation with metabolic parameters or insulin resistance. RBP4 liver tissue immunostaining was more extensive and intense in NAFLD liver compared with normal liver and the RBP4 immunohistochemical score was positively correlated with the grade of steatosis, grade of non‐alcoholic steatohepatitis activity and stage of fibrosis.Conclusions: In NAFLD patients, serum RBP4 was significantly lower as compared with controls and did not correlate with insulin resistance. In contrast, RBP4 liver tissue expression was enhanced and correlated with NAFLD histology.
- 30 September 2009
- Published by Wiley in Hepatology Research
- Vol. 39 (10) , 972-978
Circulating and liver tissue levels of retinol‐binding protein‐4 in non‐alcoholic fatty liver disease
Aim: Retinol‐binding protein‐4 (RBP4) has been proposed as a new adipokine that regulates insulin action in muscles and the liver, and contributes to the pathogenesis of insulin resistance. As non‐alcoholic fatty liver disease (NAFLD) is related to insulin resistance, we aimed to evaluate RBP4 levels in the serum and liver of patients with NAFLD.Methods: Serum RBP4 was measured in 30 NAFLD patients and 30 matched healthy controls. RBP4 expression in the liver of NAFLD patients was shown by immunohistochemistry.Results: Serum RPB4 was significantly lower in NAFLD patients compared with controls (25.15 vs 34.66 µg/mL, P < 0.001) and there was no correlation with metabolic parameters or insulin resistance. RBP4 liver tissue immunostaining was more extensive and intense in NAFLD liver compared with normal liver and the RBP4 immunohistochemical score was positively correlated with the grade of steatosis, grade of non‐alcoholic steatohepatitis activity and stage of fibrosis.Conclusions: In NAFLD patients, serum RBP4 was significantly lower as compared with controls and did not correlate with insulin resistance. In contrast, RBP4 liver tissue expression was enhanced and correlated with NAFLD histology.
- Open Access
- 27 April 2009
- Published by Wolters Kluwer Health in Hepatology
- Vol. 49 (5) , 1783-1784
Values for upper limit of normal should be given for liver enzymes #
- 27 April 2009
- Published by Wolters Kluwer Health in Hepatology
- Vol. 49 (5) , 1783-1784
Open AccessValues for upper limit of normal should be given for liver enzymes #